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The most common paradoxical manifestations related to tumour 
necrosis factor (TNF) antagonists include psoriasiform skin lesions 
and the occurrence of arthralgia, which have been observed in 
patients with Crohn’s disease and ulcerative colitis treated with 
anti-TNFs.1 Nevertheless, these drugs are successfully used to treat 
patients with psoriasis and rheumatoid arthritis. Given that these 
symptoms can also occur as extra-intestinal manifestations of 
inflammatory bowel disease (IBD), their management is challenging.
Drug exposure has been brought forward as a contributing fac-
tor but has never been studied in detail. In this issue of JCC, two 
studies from the Netherlands2 and France3 have sought to prospec-
tively evaluate the association between TNF antagonist trough con-
centrations (i.e. the serum drug concentration just before the next 
administration of drug) and the occurrence of drug-induced para-
doxical manifestations. Outcome measures included health- and dis-
ease-related quality of life questionnaires completed by the patient 
for the study by Brandse et  al.2 and a physician’s assessment and 
confirmation by a specialist (dermatologist or rheumatologist) for 
the study by Coutzac et al.3
Both studies enrolled patients with IBD on anti-TNF main-
tenance therapy (infliximab or adalimumab for the Dutch study 
and infliximab for the French study). The study by Brandse et al. 
ruled out active disease by measuring faecal calprotectin and 
C-reactive protein (CRP) at baseline, whereas in the study by 
Coutzac et al. patients with various disease states were included. 
Interestingly, in the French study a trend towards lower trough 
concentrations was observed for patients with arthralgia com-
pared with controls, possibly related to uncontrolled inflamma-
tion and extra-intestinal symptoms, rather than drug-induced 
paradoxical manifestations. Indeed, higher CRP concentrations 
were observed in cases than in controls. As also mentioned in 
the study by Brandse et al., among those patients who reported 
adverse symptoms there were two types: patients who experi-
enced symptoms in the first days after anti-TNF administration 
(possibly related to immunological response mechanisms) and 
those who developed symptoms in the days before the next 
administration (possibly due to subclinical relapsing disease 
activity).
Despite these differences in patient populations, both studies con-
cluded that psoriasiform skin manifestations and arthralgia were not 
associated with higher drug trough concentrations. Unfortunately, the 
relatively small sample size in both studies precluded meaningful sub-
group analyses. Nevertheless, the current studies confirm results from 
a previous large retrospective cohort study of 604 IBD patients treated 
with anti-TNF, in which, in addition to trough concentrations, no dif-
ference was observed in the cumulative dose of infliximab between 
patients developing psoriasiform skin lesions and those who did not.4
Although the results were straightforward, one can argue 
whether in this case trough concentrations are the most appropriate 
measures to evaluate overall drug exposure, as peak concentrations 
or area under the curve could have been better pharmacokinetic 
parameters to investigate. Trough concentrations have been shown 
to be valuable in guiding individualized dosing in IBD patients 
responding to maintenance infliximab therapy. Especially in the set-
ting of supra-optimal drug concentrations, therapeutic drug moni-
toring can guide dose reduction to achieve an optimal exposure 
level and reduce drug costs.5 Besides cost savings, this might also 
have a beneficial influence on the patient’s quality of life as an asso-
ciation between supra-optimal drug concentrations and impaired 
quality of life was observed in the study of Brandse et al.2 Although 
statistically significant, the question remains whether the difference 
in IBD questionnaire score between patients with high versus low 
drug exposure (176 and 187 respectively) is clinically meaningful.
In conclusion, when defining drug-induced arthralgia, under-
lying intestinal inflammation should be ruled out by an objective 
marker such as CRP or faecal calprotectin as patients with symp-
toms due to active disease, paradoxically, might benefit from a 
dose increase. It is clear that, for now at least, the true value of 
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therapeutic drug monitoring lies in maximizing the cost-benefit of 
anti-TNF therapy, rather than in preventing and treating safety-
related manifestations.
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